FDA approves Novo Nordisk's higher-dose Wegovy for obesity patients

Novo Nordisk NVO announced that the FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction in the long term. NVO expects to launch Wegovy HD in a single-dose pen in the United States in April 2026. The FDA granted a Commissioner’s National Priority Voucher for Wegovy HD, expediting its review and highlighting its potential to meet critical patient needs and broader U.S....